Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

67.94
-1.9599-2.80%
Volume:185.26K
Turnover:12.71M
Market Cap:5.45B
PE:7.60
High:70.43
Open:68.45
Low:67.26
Close:69.90
52wk High:87.50
52wk Low:35.95
Shares:80.29M
Float Shares:65.01M
Volume Ratio:3.29
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.94
EPS(LYR):-4.7276
ROE:-7740.12%
ROA:25.70%
PB:-35.02
PE(LYR):-14.37

Loading ...

RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating

MT Newswires Live
·
1 hour ago

PTC Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
2 hours ago

RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
2 hours ago

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
2 hours ago

Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics

TIPRANKS
·
2 hours ago

PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating

TIPRANKS
·
4 hours ago

U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler

Reuters
·
7 hours ago

PTC Therapeutics Inc : RBC Cuts Target Price to $82 From $87

THOMSON REUTERS
·
10 hours ago

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Disposes of Common Shares

Reuters
·
16 hours ago

Earnings Flash (PTCT) PTC Therapeutics Posts Q4 Loss $1.67 per Share

MT Newswires Live
·
17 hours ago

PTC Therapeutics Inc. Publishes Corporate Presentation Highlighting Sephience Launch and Pipeline Progress

Reuters
·
17 hours ago

PTC Therapeutics reports Q4 EPS ($1.67), consensus (41c)

TIPRANKS
·
17 hours ago

PTC Therapeutics sees 2026 product revenue up 19%-36%to $700M-$800M

TIPRANKS
·
17 hours ago

PTC Therapeutics Q4 EPS $(1.67) Misses $0.07 Estimate, Sales $164.677M Miss $276.665M Estimate

Benzinga
·
17 hours ago

PTC Therapeutics posts FY 2025 total revenues of USD 1.73B**2.15x**

Reuters
·
17 hours ago

BRIEF-PTC Therapeutics Q4 Net Income USD -134.965 Million

Reuters
·
17 hours ago

PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside

Simply Wall St.
·
Feb 18

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 13

BUZZ-PTC Therapeutics falls after withdrawing muscle disorder drug marketing application

Reuters
·
Feb 13

PTC Therapeutics Withdraws Translarna NDA After FDA Feedback

TIPRANKS
·
Feb 13